X4 Pharmaceuticals Inc

Stock Chart, Company Information, and Scan Results

$4.16(as of Dec 30, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

X4 Pharmaceuticals Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$4.16
Ticker SymbolXFOR
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees143
CountyUSA
Market Cap$376.0M
EBIDTA-90.4M
10-Day Moving Average4.01
P/E Ratio-0.32
20-Day Moving Average3.86
Forward P/E Ratio0.00
50-Day Moving Average3.73
Earnings per Share-8.92
200-Day Moving Average3.70
Profit Margin-1,689.24%
RSI56.83
Shares Outstanding87.4M
ATR0.31
52-Week High24.45
Volume461,465
52-Week Low1.35
Most Recent Support Level3.50
Book Value61.6M
Most Recent Resistance Level4.56
P/B Ratio0.50
Upper Keltner4.55
P/S Ratio0.91
Lower Keltner3.17
Debt-to-Equity Ratio4.55
Next Earnings DateUnknown
Cash Surplus46.4M
Next Ex-Dividend DateUnknown

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications; and with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand. The company is headquartered in Boston, Massachusetts.

X4 Pharmaceuticals Inc In Our Stock Scanner

As of Dec 31, 2025
example chart graphic
Scan Name: Golden CrossScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Low PS RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.